Disease · MONDO_0005133

endometriosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. endometriosis. Diseases, record MONDO_0005133. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005133

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: endometriosis; Open Targets
Open Targets ID: MONDO_0005133; Open Targets
Other names: ENDOMETRIOSIS NEC, Endometriosis (clinical), Endometriosis (disorder), Endometriosis (morphologic abnormality), Endometriosis NOS, Endometriosis NOS (disorder), Endometriosis of other specified sites, Endometriosis, site unspecified, endometriosis (disease); Open Targets
Disease Ontology: DOID:289; Disease Ontology
MeSH: D004715; MeSH
NCI Thesaurus: C3014; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 90 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs90

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DIENOGEST	CHEMBL1201864	Small molecule	Approval	PMDA and TTD	25	23	23	Drugs and targets
NORETHINDRONE ACETATE	CHEMBL1201146	Small molecule	Approval	DailyMed	13	12	12	Drugs and targets
ETHINYL ESTRADIOL	CHEMBL691	Small molecule	Approval	PMDA	10	9	7	Drugs and targets
DROSPIRENONE	CHEMBL1509	Small molecule	Approval	PMDA	6	5	3	Drugs and targets
DANAZOL	CHEMBL1479	Small molecule	Approval	DailyMed	6	4	4	Drugs and targets
MEDROXYPROGESTERONE ACETATE	CHEMBL717	Small molecule	Approval	DailyMed	5	4	3	Drugs and targets
NAFARELIN	CHEMBL1201309	Protein	Approval	TTD	2	1	1	Drugs and targets
ELAGOLIX SODIUM	CHEMBL502182	Small molecule	Approval	DailyMed, FDA and TTD	3	0	0	Drugs and targets
HISTRELIN	CHEMBL1201255	Protein	Approval	TTD	1	0	0	Drugs and targets
NAFARELIN ACETATE	CHEMBL1200671	Protein	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 90

See all 90 drugs

Targets132

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	18	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
PGR	Progesterone receptor	17	Progesterone receptor agonist; Progesterone receptor antagonist; Progesterone receptor modulator	Approval	https://conductscience.org/library/genes/5241	Drugs and targets
ESR1	Estrogen receptor	5	Estrogen receptor agonist; Estrogen receptor alpha agonist; Estrogen receptor alpha modulator; Estrogen receptor modulator	Approval	https://conductscience.org/library/genes/2099	Drugs and targets
ESR2	Estrogen receptor	3	Estrogen receptor agonist; Estrogen receptor beta agonist; Estrogen receptor beta modulator	Phase 2	https://conductscience.org/library/genes/2100	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	3	Follicle stimulating hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/2492	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	3	Luteinizing hormone/Choriogonadotropin receptor agonist	Phase 3	https://conductscience.org/library/genes/3973	Drugs and targets
AR	Androgen receptor	2	Androgen Receptor agonist; Androgen Receptor antagonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
CYP19A1	Aromatase	2	Cytochrome P450 19A1 inhibitor	Phase 2	https://conductscience.org/library/genes/1588	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2324	Drugs and targets

1 to 10 of 132

See all 132 targets

Trials126

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03213457	A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain	Phase 3	681	2021-04-20	Endometriosis	ELAGOLIX, ESTRADIOL, NORETHINDRONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT02203331	Bay98-7196, Dose Finding / POC Study	Phase 2	319	2018-01-04	Endometriosis	ANASTROZOLE, LEVONORGESTREL	Its record names the disease	ClinicalTrials.gov
NCT03232281	Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis	Phase 3	300	2021-10-14	Endometriosis	TRIPTORELIN ACETATE, TRIPTORELIN PAMOATE	Its record names the disease	ClinicalTrials.gov
NCT00437658	Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis	Phase 2	252	2018-10-12	Endometriosis	ELAGOLIX, MEDROXYPROGESTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT04614246	Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb	Phase 2	215	2023-05-31	Endometriosis	ELAGOLIX, ELIAPIXANT	Its record names the disease	ClinicalTrials.gov
NCT05103228	Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders	Not applicable	190	2024-12-13	Infertility, Ovarian Dysfunction	FOLLITROPIN ALFA, FOLLITROPIN DELTA	Its record names the disease	ClinicalTrials.gov
NCT01269125	GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.	Not applicable	180	2013-07-24	Endometriosis, Infertility	LEUPROLIDE	Its record names the disease	ClinicalTrials.gov
NCT00797225	Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis	Phase 2	174	2018-09-10	Endometriosis	ELAGOLIX	Its record names the disease	ClinicalTrials.gov
NCT00619866	An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis	Phase 2	155	2018-09-07	Endometriosis, Pain	ELAGOLIX	Its record names the disease	ClinicalTrials.gov
NCT00973973	Efficacy and Safety Study of Elagolix in Women With Endometriosis	Phase 2	137	2018-09-26	Endometriosis, Pain	ELAGOLIX	Its record names the disease	ClinicalTrials.gov

1 to 10 of 126

See all 126 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: deaths from any cause	0 of 149	0 of 150	299	NCT03232281	Trial comparisons
Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: serious adverse events	2 of 149	1 of 150	299	NCT03232281	Trial comparisons
Elagolix vs Placebo: deaths from any cause	0 of 131	0 of 69	200	NCT00973973	Trial comparisons
Elagolix vs Placebo: serious adverse events	1 of 131	3 of 69	200	NCT00973973	Trial comparisons
Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: Cumulative Clinical Pregnancy Rate	27 of 94	17 of 91	185	NCT05103228	Trial comparisons
Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: deaths from any cause	0 of 94	1 of 91	185	NCT05103228	Trial comparisons
Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: serious adverse events	0 of 94	0 of 91	185	NCT05103228	Trial comparisons
Intervention Group vs Placebo Group: serious adverse events	8 of 25	5 of 26	51	NCT00474851	Trial comparisons
Tanezumab vs Placebo: serious adverse events	0 of 22	3 of 25	47	NCT00784693	Trial comparisons
Tanezumab vs Placebo: Number of Participants With Positive Urine or Serum Pregnancy Test	0 of 22	0 of 23	45	NCT00784693	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials72

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33280722	RESULT	1	PubMed
33272623	RESULT	1	PubMed
32819842	RESULT	1	PubMed
32211953	RESULT	1	PubMed
31838515	RESULT	1	PubMed
31096979	RESULT	1	PubMed
30594482	RESULT	1	PubMed
30196963	RESULT	1	PubMed
29935660	RESULT	1	PubMed
29121326	RESULT	1	PubMed

1 to 10 of 72

See all 72 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005133

GET https://conductscience.org/api/diseases/v1/MONDO_0005133/drugs?page=2

API reference For AI assistants